Audit: QRS - Massularia acuminata for Health & Longevity

Audit conducted on 19/08/2026 23:34 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol values, marker targets, cadence, gate items, benefit/risk labels and qualitative items trace to ER lines 264–271, 242–262, 293–297, 348, 376–396.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“explicitly an estimate, not a validated dose”, “no published clinical rationale”, “No human time-course has ever been measured”, “theoretical androgen-sensitive risk” all mirror the ER.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications remain absolute; the nitrate/riociguat bullet stays in the stop gate, not the caution gate.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Stop and caution items come only from Key Interactions & Contraindications; no Benefit- or Risk-Modifying Factor is surfaced.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, citations, expert names, NCT identifiers or brand names at all.
1.6	The QRS does not introduce new attributions.	🟢	No attributions appear anywhere in the QRS body.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s restrained, evidence-thin framing throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Targets, thresholds and cadence are concrete; language is neutral and non-alarmist.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents thresholds and intervals as evidence, not orders.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative clinical instructions; the footer disclaimer is the template’s own.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommend”, “advise” or “should” constructions in the QRS voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Enzymes and hormones are written out in full rather than abbreviated.
2.8	Information is presented in a concise and very compact manner	🟢	Gate items, benefit/risk items and marker rows are single-clause entries.
2.9	It DOES NOT address the reader directly	🟢	Confirmed; no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional-range targets and an 11-marker panel address a proactive, testing-oriented audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Repeated liver panels, hormone panels and semen analysis assume that willingness.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content is calibrated well above general-population effort.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance foregrounds the empty human record, the decision-relevant point for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“aminotransferase”, “gonadotropins”, “decoction”, “phosphodiesterase-5 inhibitors” used throughout.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings byte-identical to QRS.html (lines 437, 474, 516, 553, 572, 603, 536, 542, 576–578).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable spans present; marker_#_* and qualitative_item_# correctly expanded to 11 and 5 instances.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	website="evidence_review", website="audit" and website="full_review" are untouched; footer disclaimer unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standardised extract capsules”, “Body-weight-scaled estimate”, “Traditional West African use” match the ER bold labels at lines 293–297 verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Benefit and risk labels reproduce the ER #### headings; marker names reproduce the ER biomarker table column 1.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the QRS; the ER’s ⚠️ Conflicted markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Template print rules unchanged; every section is condensed to single-clause entries with no added blocks or overflow markup.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the caption text on line 2 precedes it.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: massularia_acuminata_2026-0825-2106_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0819-2317.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” = nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s own name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across lines 4–12; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Massularia acuminata for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Massularia acuminata for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/19/2026”, matching qrs_creation_date: 2026-0819-2317.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template subline; the ER’s “Also known as” line is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER lines 416–422: the two traditional uses, the single human comparison, the rodent-only claims, the harms, and the empty human record.
7.2	[at_a_glance] is no longer than 60 words	🟢	53 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each of the five clauses maps to a distinct sentence in the ER Conclusion (lines 416, 418, 420, 422).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Uses “tooth-cleaning stick”, “strength tonic”, “blood-sugar”, “sperm harms”; no acronyms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	Only “One small human comparison” — no name, year or sample size.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric results appear.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All six items derive from the ER’s “Populations who should avoid” list, lines 266–271.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All six ER avoidance populations are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 542–547 are six discrete <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing rationales “pending evaluation”, “given the adulteration rate in this product category” and “on absence-of-data grounds” are all stripped; no dash-trailing clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“Child-Pugh Class B or C”, “above 3× the upper limit of normal”, “above 4 ng/mL”, “within 3 months”, “under 18” all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names six such populations, and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items map to ER bullets at lines 242–262.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	The nitrate/riociguat bullet (ER line 244) is correctly omitted here and carried in the stop gate instead.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 555–564 are ten discrete <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER “Consequence:” and “Mitigation:” clause is stripped; only the agent class and its examples remain.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named example drugs retained in all nine parenthesised items; longer lists trimmed to three exemplars rather than dropped.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER lists eleven interaction bullets, and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from the ER Therapeutic Protocol bullets at lines 293, 295 and 297.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The commercial serving, the body-weight-scaled estimate and the traditional preparation are the ER’s three dosing routes.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct actionable aspects; no set is unused.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated; “~300 mg once daily”, “550–900 mg” and “Chewed stem or boiled decoction” all trace to ER lines 293–297.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER’s “Time to effect” bullet (line 348) names exactly two aspects, oral hygiene and the hormonal claim, and both are carried.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Oral hygiene (Medium tier) precedes the hormonal claim (Low tier).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	🟢	The third pcell carries style="display: none" with empty time_3_* spans (lines 503–513).
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“6 weeks” and “1 to 5 days in rats” with their subs match ER line 348 verbatim in substance.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All five benefit names reproduce the ER #### headings at lines 134, 142, 148, 154 and 162.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 521, 524, 527 and 530.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Bare heading names only; no Magnitude text or study detail carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content appears in any benefit item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER has no High benefit; benefits_high carries style="display: none" with an empty label (line 521).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All six risk names reproduce the ER #### headings at lines 188, 196, 202, 210, 218 and 222.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 576, 579, 582 and 585.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Bare heading names only; the ⚠️ Conflicted markers and Magnitude figures are dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content appears in any risk item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	The ER populates all four risk tiers, so no sub-section is empty.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows reproduce the ER Monitoring Protocol & Defining Success biomarker table, lines 376–388.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 11 ER biomarkers present, in ER order, with targets carried verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 728 condenses the ER’s cadence sentence (line 374) into liver panel, hormone and prostate-specific antigen intervals.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Items reproduce the ER’s “Qualitative markers worth tracking” list, lines 392–396.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers present, in ER order.

Issues 19/08/2026 23:34

Pass rate 100.00%. No issues found.

Issues 19/08/2026 23:27

1. 4.5 — Content overruns one A4 page: The sheet renders to roughly 1.8 A4 pages; the eleven-row Monitoring table (lines 603–723) and the ten [caution_items] (lines 555–564) both wrap to two lines per entry, and the cadence line (line 728) and several protocol sub-lines add further overflow.

Fixes 19/08/2026 23:27

1. 4.5 — Monitoring “Why” cells condensed: Shortened six explanations so each fits a single line, e.g. “Distinguishes a pituitary-level effect, the proposed mechanism, from a testicular one” to “Distinguishes a pituitary-level effect from a testicular one”.
2. 4.5 — Monitoring targets tightened: Reduced the wrapping targets, e.g. “Concentration above 16 million/mL, total motility above 42%” to “Above 16 million/mL; motility above 42%” and the alanine aminotransferase parentheticals to plain “Under 25 U/L men, under 20 U/L women”.
3. 4.5 — Monitoring cadence shortened: Rewrote the cadence line from “Full liver panel before starting, repeated at 4 weeks and again at 8 weeks, then at the end of every subsequent course…” to “Liver panel before starting, at 4 and 8 weeks, then after every subsequent course…”.
4. 4.5 — Key Interactions example lists trimmed: Shortened seven interaction items so most fit one line in the half-width gate, trimming example drug lists rather than dropping them (e.g. hepatotoxic botanicals now “green tea extract, kava, comfrey”).
5. 4.5 — Contraindications tightened: Condensed four gate items, e.g. “Child-Pugh Class B or C liver impairment (moderate to severe cirrhosis), or aspartate or alanine aminotransferase above 3× the upper limit of normal” to “Child-Pugh Class B or C liver impairment, or aminotransferases above 3× the upper limit of normal”.
6. 4.5 — Protocol sub-lines condensed: Shortened all three action sub-lines, e.g. the body-weight-scaled cell now reads “550 mg at 68 kg, 700 mg at 91 kg, 900 mg at 113 kg; explicitly an estimate, not a validated dose.”
7. 4.5 — Qualitative items trimmed: Removed two trailing words from the morning-erection and hepatic-symptom items to keep both on one line each.

Issues 19/08/2026 23:21

1. 12.3 / 13.3 — Conflicted qualifier not stripped: The benefit “Oral Hygiene and Gingival Health (conflicted)” (line 525) and the risk “Liver Enzyme Disturbance (conflicted)” (line 580) retain an evidence-strength qualifier; the tier label already encodes evidence strength, so the parenthetical is redundant detail that the concision rule requires be removed.

Fixes 19/08/2026 23:21

1. 12.3 / 13.3 — Conflicted qualifier stripped: Removed the “(conflicted)” qualifier from the Benefits item “Oral Hygiene and Gingival Health (conflicted)” and from the Risks item “Liver Enzyme Disturbance (conflicted)”, leaving the bare tiered descriptors.